Reduced p21WAF1/CIP1 via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 1895-1905

  Wu, De Wei ^a   Liu, Wen Shan ^a   Wang, John ^b   Chen, Chih Yi ^c   Cheng, Ya Wen ^d   Lee, Huei ^a,d,e  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; DDX3 PROTEIN; DEAD BOX PROTEIN; KI 67 ANTIGEN; PROTEIN E6; PROTEIN P53; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EARLY CANCER; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LUNG CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE FREE SURVIVAL; TRANSCRIPTION REGULATION; TUMOR GROWTH;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEAD-BOX RNA HELICASES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMAN PAPILLOMAVIRUS 16; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LUCIFERASES; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, VIRAL; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79953305455     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2316     Document Type: Article

References (40)

1. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nature reviews 2007;7:778-90. (Pubitemid 47463669)
2. Thun MJ, Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, Feskanich D, et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS medicine 2008;5:e185.
3. Cheng YW, Lee H. Environmental exposure and lung cancer among nonsmokers: an example of Taiwanese female lung cancer. J Environ Sci Health 2003;21:1-28. (Pubitemid 36666850)
4. Department of Health. Annual Report of Cancer Incidence, 1979-2008. Taipei, Taiwan: Department of Health; 2009.
5. Cheng YW, Chiou HL, Sheu GT, Hsieh LL, Chen JT, Chen CY, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001;61:2799-803.
6. Malanchi I, Caldeira S, Krutzfeldt M, Giarre M, Alunni-Fabbroni M, Tommasino M. Identification of a novel activity of human papillomavirus type 16 E6 protein in deregulating the G1/S transition. Oncogene 2002;21:5665-72. (Pubitemid 35332999)
7. Malanchi I, Accardi R, Diehl F, Smet A, Androphy E, Hoheisel J, et al. Human papillomavirus type 16 E6 promotes retinoblastoma protein phosphorylation and cell cycle progression. J Virol 2004;78:13769-78. (Pubitemid 39612774)
8. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
9. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994;211:90-8. (Pubitemid 24167339)
10. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Bertacca G, et al. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996;12:1319-24.
11. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4. (Pubitemid 24036020)
12. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12. (Pubitemid 29297917)
13. Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, et al. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002;20:3865-71.
14. Komiya T, Hosono Y, Hirashima T, Masuda N, Yasumitsu T, Nakagawa K, et al. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 1997;3:1831-5. (Pubitemid 27444724)
15. Caputi M, Esposito V, Baldi A, De Luca A, Dean C, Signoriello G, et al. p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. Am J Respir Cell Mol Biol 1998;18:213-7. (Pubitemid 128355240)
16. Esposito V, Baldi A, Tonini G, Vincenzi B, Santini M, Ambrogi V, et al. Analysis of cell cycle regulator proteins in non-small cell lung cancer. J Clin Pathol 2004;57:58-63. (Pubitemid 38091312)
17. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001;61:6234-8.
18. Cheng YW, Wu MF, Wang J, Yeh KT, Goan YG, Chiou HL, et al. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 2007;67:10686-93. (Pubitemid 350145894)
19. Rosner A, Rinkevich B. The DDX3 subfamily of the DEAD box helicases: divergent roles as unveiled by studying different organisms and in vitro assays. Curr Med Chem 2007;14:2517-25. (Pubitemid 47618039)
20. Chang PC, Chi CW, Chau GY, Li FY, Tsai YH, Wu JC, et al. DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control. Oncogene 2006;25:1991-2003.
21. Chao CH, Chen CM, Cheng PL, Shih JW, Tsou AP, Lee YH. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor. Cancer Res 2006;66:6579-88.
22. Sekiguchi T, Kurihara Y, Fukumura J. Phosphorylation of threonine 204 of DEAD-box RNA helicase DDX3 by cyclin B/cdc2 in vitro. Biochem Biophys Res Commun 2007;356:668-73. (Pubitemid 46499016)
23. Chang K, Elledge SJ, Hannon GJ. Lessons from Nature: microRNA-based shRNA libraries. Nat Methods 2006;3:707-14. (Pubitemid 44275738)
24. Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002;21:6041-8.
25. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y, et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 2003;8:762-8.
26. Cheng YW, Wu TC, Chen CY, Chou MC, Ko JL, Lee H. Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus-16/18-infected lung tumorigenesis. Clin Cancer Res 2008;14:7173-9.
27. Lahn BT, Page DC. Functional coherence of the human Y chromosome. Science 1997;278:675-80. (Pubitemid 27464964)
28. Sharma D, Fondell JD. Ordered recruitment of histone acetyltransferases and the TRAP/Mediator complex to thyroid hormone-responsive promoters in vivo. Proc Natl Acad Sci U S A 2002;99:7934-9. (Pubitemid 34650983)
29. Wu HH, Cheng YW, Chang JT, Wu TC, Liu WS, Chen CY, et al. Subcellular localization of apurinic endonuclease 1 promotes lung tumor aggressiveness via NF-kappaB activation. Oncogene 2010;29:4330-40.
30. Sekiguchi T, Iida H, Fukumura J, Nishimoto T. Human DDX3Y, the Y-encoded isoform of RNA helicase DDX3, rescues a hamster temperature-sensitive ET24 mutant cell line with a DDX3X mutation. Exp Cell Res 2004;300:213-22. (Pubitemid 39286230)
31. Koutsodontis G, Tentes I, Papakosta P, Moustakas A, Kardassis D. Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein. J Biol Chem 2001;276:29116-25.
32. Hommura F, Dosaka-Akita H, Mishina T, Nishi M, Kojima T, Hiroumi H, et al. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 2000;6:4073-81.
33. Dosaka-Akita H, Hommura F, Mishina T, Ogura S, Shimizu M, Katoh H, et al. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis. Cancer Res 2001;61:2500-4.
34. Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003;21:3391-401. (Pubitemid 46594071)
35. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004;91:2018-25. (Pubitemid 40128768)
36. Niemiec J, Kolodziejski L, Dyczek S. EGFR LI and Ki-67 LI are independent prognostic parameters influencing survivals of surgically treated squamous cell lung cancer patients. Neoplasma 2005;52:231-7. (Pubitemid 40776435)
37. Shiba M, Kohno H, Kakizawa K, Iizasa T, Otsuji M, Saitoh Y, et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma. Cancer 2000;89:1457-65.
38. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9:400-14.
39. Dworakowska D, Jassem E, Jassem J, Boltze C, Wiedorn KH, Dworakowski R, et al. Absence of prognostic significance of p21(WAF1/CIP1) protein expression in non-small cell lung cancer. Acta Oncol 2005;44:75-9. (Pubitemid 40249131)
40. Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog 2009;5:e1000318.